Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
This study has been completed.
Study NCT00957372 Information provided by Bial - Portela C S.A.
First Received on August 10, 2009. Last Updated on June 23, 2014
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Central Nervous System Diseases
Nervous System Diseases
Interventions listed in this trial
placebo (Part I)
More general drug interventions related to this trial
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Sodium Channel Blockers
Voltage-Gated Sodium Channel Blockers
Sponsors listed in this trial
Bial - Portela C S.A.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers